InsiderTrades

Form 4 for XERS Xeris Biopharma Holdings, Inc.

Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-12 · accession 0002031695-26-000006 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-03-16 2026-03-12 XERS McCulloch Kevin See Remarks M - OptEx $4.09 +48.9K 1.78M +3% +$200.0K
DM 2026-03-16 2026-03-12 XERS McCulloch Kevin See Remarks M - OptEx $4.09 -48.9K 43.8K -53% -$200.0K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-12 M A 48,894 $4.09 1,777,721 D — —
2 Common Common Stock 2026-03-12 M A 4 $3.94 1,777,725 D — —
3 Derivative Stock Option (Right to Buy) 2026-03-12 M D 4 $3.94 79,996 D $3.94 · — to 2030-08-26 4 Common Stock (F3) The reporting person received the stock options on August 26, 2020 pursuant to an award under the 2018 Plan. 50% of the options vested on the first anniversary of the vesting commencement date, 25% of the options vested on the 18-month anniversary of the vesting commencement date, and the remaining 25% of options vested on the two-year anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.
4 Derivative Stock Option (Right to Buy) 2026-03-12 M D 48,894 $4.09 43,773 D $4.09 · — to 2027-12-10 48,894 Common Stock (F2) The reporting person received the stock options on December 10, 2020 pursuant to an award under the Company's 2018 Stock Option/Stock Issuance Plan (the "2018 Plan"). 50% of the options vested on the first anniversary of the vesting commencement date, and the remaining 50% of options vested on the second anniversary of the vesting commencement date, in each case subject to continued employment through such vesting date.